These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Chen L, Su H, Shao H, Xu K, Liang S, Liu J. Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077 [Abstract] [Full Text] [Related]
5. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY, Paik YH, Lim HY, Kim YG, Lim HK, Min YW, Gwak GY, Choi MS, Lee JH, Koh KC, Paik SW, Yoo BC. Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [Abstract] [Full Text] [Related]
9. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions. Lee SH, Song IH, Noh R, Kang HY, Kim SB, Ko SY, Lee ES, Kim SH, Lee BS, Kim AN, Chae HB, Kim HS, Lee TH, Kang YW, Lee JD, Lee HY. BMC Cancer; 2015 Apr 08; 15():236. PubMed ID: 25885683 [Abstract] [Full Text] [Related]
10. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. Ziogas DC, Papadatos-Pastos D, Thillai K, Korantzis I, Chowdhury R, Suddle A, O'Grady J, Al-Khadimi G, Allen N, Heaton N, Ross PJ, Sarker D. Eur J Gastroenterol Hepatol; 2017 Jan 08; 29(1):48-55. PubMed ID: 27623000 [Abstract] [Full Text] [Related]
13. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice. Lee IC, Chen YT, Chao Y, Huo TI, Li CP, Su CW, Lin HC, Lee FY, Huang YH. Medicine (Baltimore); 2015 Apr 08; 94(14):e688. PubMed ID: 25860213 [Abstract] [Full Text] [Related]
15. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. Yoon EL, Yeon JE, Lee HJ, Suh SJ, Lee SJ, Kang SH, Kang K, Yoo YJ, Kim JH, Yim HJ, Byun KS. J Clin Gastroenterol; 2014 Mar 08; 48(3):e22-9. PubMed ID: 24045282 [Abstract] [Full Text] [Related]
16. Efficacy of Sorafenib for Advanced Hepatocellular Carcinoma and Prognostic Factors. Li J, Wang L, Cong N, Shi C, Bu W, Song J, Chen H. Hepatogastroenterology; 2014 Jun 08; 61(132):954-7. PubMed ID: 26158148 [Abstract] [Full Text] [Related]
17. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function. Yang H, Woo HY, Lee SK, Han JW, Jang B, Nam HC, Lee HL, Lee SW, Song DS, Song MJ, Oh JS, Chun HJ, Jang JW, Lozada A, Bae SH, Choi JY, Yoon SK. Clin Mol Hepatol; 2017 Jun 08; 23(2):128-137. PubMed ID: 28494528 [Abstract] [Full Text] [Related]
18. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial. Vilgrain V, Abdel-Rehim M, Sibert A, Ronot M, Lebtahi R, Castéra L, Chatellier G, SARAH Trial Group. Trials; 2014 Dec 03; 15():474. PubMed ID: 25472660 [Abstract] [Full Text] [Related]
19. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study. Nada Y, Rashad N, Eissa M, Ghonaim A, Farag K, Saadawi I, Sheha A, El Gewaity M, Abdel-Rahman O. Expert Rev Gastroenterol Hepatol; 2018 Jan 03; 12(1):99-107. PubMed ID: 29124987 [Abstract] [Full Text] [Related]
20. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study. Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T, Kurume Liver Cancer Study Group of Japan. Cancer Med; 2015 Dec 03; 4(12):1836-43. PubMed ID: 26471348 [Abstract] [Full Text] [Related] Page: [Next] [New Search]